Nowoczesne metody diagnostyki kardiotoksycznosci antracyklin u pacjentow z chloniakami


Author(s): Beata Kumiega, Andrzej Pluta, Jacek Krzanowski

Anthracyclines, show a strong antitumour activity in the treatment of solid and haematological malignancies. They may be responsible for cardiac side effects. Initially, cardiac damage induced by anthracyclines is subclinical, however increasingly impaired cardiac function can result chronic heart failure. The assessment of the myocardial damage, especially at its initial stage is very important however difficult. There is a continuous need for new methods introduction of early detection of cardiac damage.

Share this article

Editors List

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)